Exabis Library
Welcome to the e-CCO Library!
P439 Patient’ recruitment for a Phase 3 inflammatory bowel disease (IBD) programme is significantly increased when accessing the CT-SCOUT™ platform
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P439: Diagnosis and management of latent and active tuberculosis in the context of biologic therapy in inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P439: Effectiveness and safety of the sequential use of a second and third anti-TNF agent in patients with inflammatory bowel disease: results from the ENEIDA registry
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P439: Effectiveness of a training programme on motivational interviewing skills applied to inflammatory bowel disease management
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P439: Effectiveness of Ustekinumab on Crohn's disease associated spondyloartropathy: real-world data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P439: Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved quality of life in patients with Crohn's disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P439: Monitoring inflammatory Bowel disease activity in a virtual biologic clinic: The effects of proactive therapeutic drug monitoring on patient reported outcome measures
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P439: Stability of subcutaneous serum IFX (CTP13) levels between two injections and over two successive cycles in patients with Crohn's disease.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P440 Polimedication in patients with inflammatory bowel disease: prevalence and outcomes in a retrospective unicentric series
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P440: Comparison of infliximab serum levels between venous and capillary blood in paediatric IBD patients using novel blood sampling technology
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P440: Early changes in the pharmacokinetic profile of vedolizumab-treated patients with inflammatory bowel disease may predict response after dose optimisation
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P440: First results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID)
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P440: Loss of response and dose escalation of infliximab and adalimumab in Ulcerative Colitis patients: A Systematic Review and Meta-analysis.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P440: Prevalence of NUDT15 polymorphisms and incidence of thiopurine-induced leukopenia in Inflammatory Bowel Disease patients: A systematic review and meta-analysis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P440: Staged surgical management of complicated ileo-colonic Crohn’s Disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P440: Therapeutic drug monitoring of infliximab for the management of loss of response in inflammatory bowel disease: an observational multicenter study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P441 Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P441: Adalimumab versus ustekinumab as first-line biological in a real-life cohort of moderate-to-severe Crohn's disease.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P441: Clinical efficacy, drug sustainability and results from therapeutic drug monitoring in Crohn’s disease patients treated with ustekinumab – 1-year follow-up of a prospective, nationwide, multicenter cohort from Hungary
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P441: Conjoint analysis for quantification of inflammatory bowel disease patients’ preferences for outcome metrics
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM